Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference24 articles.
1. Takahashi T, Scheibner A, Cao Q, Pearson R, Sanghavi K, Weisdorf DJ, Brunstein CG, Rogosheske J, Bachanova V, Warlick ED, Wiseman A, Jacobson PA (2021) Higher fludarabine and cyclophosphamide exposures lead to worse outcomes in reduced-intensity conditioning hematopoietic cell transplantation for adult hematologic malignancy. Transplant Cell Ther 27(773):773.e771–773.e778
2. Pinto N, Ludeman SM, Dolan ME (2009) Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10:1897–1903
3. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH (2005) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44:1135–1164
4. Kim IW, Yun HY, Choi B, Han N, Kim MG, Park S, Oh JM (2013) Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. Eur J Clin Pharmacol 69:1543–1551
5. Rocha V, Porcher R, Fernandes JF, Filion A, Bittencourt H, Silva W Jr, Vilela G, Zanette DL, Ferry C, Larghero J, Devergie A, Ribaud P, Skvortsova Y, Tamouza R, Gluckman E, Socie G, Zago MA (2009) Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 23:545–556
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献